Last updated: March 9, 2026
What is NDC 16714-0257?
NDC 16714-0257 is identified as Keytruda (pembrolizumab) 200 mg. It is an immune checkpoint inhibitor used primarily in treating melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma, and other cancers.
Market Overview
1. Therapeutic Landscape
Keytruda is a leading PD-1 inhibitor developed by Merck & Co. It accounts for approximately 70% of the U.S. market share within cancer immunotherapies[1]. Its indications expanded rapidly post-approval, covering:
- Melanoma (approved 2014)
- NSCLC (2015)
- Hodgkin lymphoma (2017)
- Other solid tumors (2017 onward)
2. Market Size and Growth
- The global oncology drug market was valued at $165 billion in 2022 and is projected to reach $484 billion by 2030, growing at a CAGR of 14.2%[2].
- Keytruda's U.S. sales for 2022 were approximately $13.2 billion, representing about 8% of the total oncology market[3].
- The drug's sales growth is driven by its broadening indications, combination therapy approvals, and ongoing clinical trials.
3. Competitive Position
Keytruda faces competition from:
- Opdivo (nivolumab, Bristol-Myers Squibb)
- Libtayo (cemiplimab, Regeneron)
- Other emerging PD-1/PD-L1 inhibitors
While Opdivo's market share is significant, Keytruda maintains leadership due to broader approved uses and ongoing clinical development.
Price Projections
1. Current Pricing
- The list price for a 200 mg dose is approximately $7,650 per vial (as of 2023)[4].
- Actual reimbursement prices vary based on payer contracts, discounts, and discounts negotiated through PBMs.
2. Historical Pricing Trends
- Since approval, the price per dose has increased marginally, aligning with inflation and R&D recovery costs.
- Medicaid and Medicare typically pay less than the list price due to rebates and negotiated discounts.
3. Price Forecasts (2023–2028)
| Year |
Estimated Average Price per 200 mg Dose |
Notes |
| 2023 |
$7,650 |
Current list price |
| 2024 |
$7,750 |
Slight increase based on inflation and inflation-adjusted list prices |
| 2025 |
$7,850 |
Potential stabilization with some price ceiling adjustments |
| 2026 |
$8,000 |
Possible introduction of value-based pricing models |
| 2027 |
$8,200 |
Increased competition or biosimilar entry could exert downward pressure |
| 2028 |
$8,300 |
Continued inflation-adjusted growth |
4. Biosimilar Impact
- No biosimilar for Keytruda is approved as of 2023, but biosimilar development is underway, potentially entering the market within 3–5 years.
- Biosimilar entry could reduce prices by 20–40%, depending on market dynamics[5].
5. Reimbursement Factors
Reimbursement rates often lower than list prices due to:
- Rebates to payers and pharmacy benefit managers (PBMs)
- Institutional discounts
- Negotiated managed care contracts
Payer pressure will influence net prices more than list prices.
Risk Factors Affecting Price and Market Penetration
- Regulatory approvals expanding or restricting uses.
- Competitive pressures from biosimilars or new therapies.
- Clinical trial outcomes influencing label extensions.
- Healthcare policies impacting drug reimbursement and pricing.
Key Takeaways
- NDC 16714-0257 (Keytruda 200 mg) dominates the immuno-oncology landscape with a robust growth trajectory.
- Market size is projected to expand as indications broaden, with global sales expected to surpass $20 billion by 2028.
- List prices remain stable with slight increases; biosimilars could significantly pressure prices once approved.
- Reimbursement always lags behind list price, moderated by rebates and negotiations.
- The competitive landscape is intensifying, putting downward pressure on prices in the mid to long term.
FAQs
Q1: What factors influence the future pricing of pembrolizumab?
A1: Market competition, biosimilar entry, clinical trial outcomes, health policy changes, and negotiated rebates.
Q2: How do biosimilars impact prices in the immuno-oncology space?
A2: Biosimilars typically reduce prices by 20–40%, increasing market competition and shifting pricing strategies.
Q3: Are there upcoming clinical trials that could expand Keytruda’s indications?
A3: Yes, ongoing trials target additional cancers and combination regimens, which could boost sales and utilization.
Q4: How does payer negotiation affect the actual cost to healthcare systems?
A4: Negotiated rebates and discounts often lower net prices compared to list prices, influencing overall expenditure.
Q5: What are the main risks to the market dominance of Keytruda?
A5: Entry of biosimilars, safety concerns, regulatory restrictions, or superior alternative therapies.
References
[1] IQVIA. (2022). Top Oncology Drugs by Revenue.
[2] MarketsandMarkets. (2023). Oncology Drugs Market Forecast.
[3] Merck & Co. Financial Reports. (2022).
[4] GoodRx. (2023). Pembrolizumab Pricing.
[5] Pharma Intelligence. (2023). Biosimilar Development Trends.
